Dr. Gerardo Colon-Otero
Claim this profileMayo Clinic in Florida
Studies Ovarian Cancer
Studies Cancer
13 reported clinical trials
21 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
Stage III
HER2 negative
2Cancer
Stage IV
HER2 negative
HR positive
Affiliated Hospitals
Clinical Trials Gerardo Colon-Otero is currently running
Vitamin D
for Prostate Cancer
This early phase I is to find out how common vitamin D insufficiency is among African American patients with a history of prostate cancer that has not spread to other parts of the body (localized) or has spread to other places in the body (metastatic) and how vitamin D insufficiency affects the immune system. This study also aims to find out if replacing vitamin D results in normalization of the immune function. Information from this study may benefit prostate cancer patients by identifying vitamin D insufficiency which in several studies had been found to contribute to more aggressive prostate cancers.
Recruiting1 award Phase < 1
Dendritic Cell Vaccine + Pembrolizumab
for Ovarian Cancer
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States. While the majority of patients achieve a remission from ovarian cancer with the combination of aggressive cytoreductive surgery and cytotoxic chemotherapy, over 80% of patients develop recurrence within 3 years of completion of treatment. Additional treatments are needed for recurrence, but the standard treatment modalities are non-curative in nature due to the development of drug resistance. As such, there is a great unmet need for treatment strategies that utilize new mechanisms to which drug resistance does not develop. FRalphaDC is a dendritic cell vaccine that is made from the white blood cells collected from a procedure call apheresis. The white blood cells are treated to make dendritic cells, which will then be incubated with peptides, which are pieces of a protein known as "folate receptor alpha" (FRalpha), a protein that is found in high levels on ovarian cancer cells. Dendritic cell vaccines work by boosting the immune system (a system in the body that protect against infection) to recognize and destroy the tumor cells by targeting the FRalpha protein. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving FRalphaDC vaccine with pembrolizumab may be a safe and effective treatment for recurrent ovarian cancer.
Recruiting1 award Phase 1 & 213 criteria
More about Gerardo Colon-Otero
Clinical Trial Related5 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Gerardo Colon-Otero has experience with
- Paclitaxel
- Bevacizumab
- Topotecan Hydrochloride
- Gemcitabine Hydrochloride
- Pegylated Liposomal Doxorubicin Hydrochloride
- Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Breakdown of trials Gerardo Colon-Otero has run
Ovarian Cancer
Cancer
Skin Cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gerardo Colon-Otero specialize in?
Gerardo Colon-Otero focuses on Ovarian Cancer and Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Gerardo Colon-Otero currently recruiting for clinical trials?
Yes, Gerardo Colon-Otero is currently recruiting for 6 clinical trials in Jacksonville Florida. If you're interested in participating, you should apply.
Are there any treatments that Gerardo Colon-Otero has studied deeply?
Yes, Gerardo Colon-Otero has studied treatments such as Paclitaxel, Bevacizumab, Topotecan Hydrochloride.
What is the best way to schedule an appointment with Gerardo Colon-Otero?
Apply for one of the trials that Gerardo Colon-Otero is conducting.
What is the office address of Gerardo Colon-Otero?
The office of Gerardo Colon-Otero is located at: Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States. This is the address for their practice at the Mayo Clinic in Florida.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.